Table 1.
Characteristics of patients who had prescriptions for once-daily teriparatide: overall, by glucocorticoid prescription, and by time frame.
| Characteristic |
All (N = 123) n (%) |
Glucocorticoidsa | Time frame of treatmentb | ||||
|---|---|---|---|---|---|---|---|
| No (N = 97) n (%) |
Yes (N = 26) n (%) |
P value | Early (N = 50) n (%) |
Later (N = 73) n (%) |
P value | ||
| Age (years) | 0.002 | 0.972 | |||||
| 55–69 | 36 (29.3) | 21 (21.6) | 15 (57.7) | 14 (28.0) | 22 (30.1) | ||
| 70–79 | 52 (42.3) | 44 (45.4) | 8 (30.8) | 22 (44.0) | 30 (41.1) | ||
| ≥80 | 35 (28.5) | 32 (33.0) | 3 (11.5) | 14 (28.0) | 21 (28.8) | ||
| Sex | 1.000 | 0.526 | |||||
| Women | 113 (91.9) | 89 (91.8) | 24 (92.3) | 45 (90.0) | 68 (93.2) | ||
| Men | 10 (8.1) | 8 (8.2) | 2 (7.7) | 5 (10.0) | 5 (6.8) | ||
| Insurance type | 0.858 | 0.246 | |||||
| Late-stage elderly healthcare | 71 (57.7) | 57 (58.8) | 14 (53.8) | 33 (66.0) | 38 (52.1) | ||
| National health insurance | 36 (29.3) | 28 (28.9) | 8 (30.8) | 13 (26.0) | 23 (31.5) | ||
| Other | 16 (13.0) | 12 (12.4) | 4 (15.4) | 4 (8.0) | 12 (16.4) | ||
| Hospital size | 0.008 | 0.002 | |||||
| <200 beds | 55 (44.7) | 50 (51.5) | 5 (19.2) | 30 (60.0) | 25 (34.2) | ||
| 200–499 beds | 41 (33.3) | 29 (29.9) | 12 (46.2) | 16 (32.0) | 25 (34.2) | ||
| ≥500 beds | 27 (22.0) | 18 (18.6) | 9 (34.6) | 4 (8.0) | 23 (31.5) | ||
| Physician speciality | <0.001 | 0.148 | |||||
| Orthopaedics | 109 (88.6) | 93 (95.9) | 16 (61.5) | 41 (82.0) | 68 (93.2) | ||
| Rheumatology | 9 (7.3) | 1 (1.0) | 8 (30.8) | 6 (12.0) | 3 (4.1) | ||
| Other | 5 (4.1) | 3 (3.1) | 2 (7.7) | 3 (6.0) | 2 (2.7) | ||
| Osteoporosis medication (any) | 82 (66.7) | 59 (60.8) | 23 (88.5) | 0.009 | 37 (74.0) | 45 (61.6) | 0.176 |
| Bisphosphonatesc | 69 (56.1) | 49 (50.5) | 20 (76.9) | 0.025 | 31 (62.0) | 38 (52.1) | 0.355 |
| Raloxifene | 23 (18.7) | 16 (16.5) | 7 (26.9) | 0.260 | 15 (30.0) | 8 (11.0) | 0.010 |
| Ipriflavone | 1 (0.8) | 1 (1.0) | 0 (0.0) | 1.000 | 1 (2.0) | 0 (0.0) | 0.407 |
| Disease-related medications | |||||||
| Vitamin D | 50 (40.7) | 36 (37.1) | 14 (53.8) | 0.177 | 26 (52.0) | 24 (32.9) | 0.041 |
| Calcium | 20 (16.3) | 15 (15.5) | 5 (19.2) | 0.765 | 13 (26.0) | 7 (9.6) | 0.024 |
| Immunosuppressants | 13 (10.6) | 4 (4.1) | 9 (34.6) | <0.001 | 4 (8.0) | 9 (12.3) | 0.557 |
| Anticonvulsants | 4 (3.3) | 2 (2.1) | 2 (7.7) | 0.196 | 2 (4.0) | 2 (2.7) | 1.000 |
| Major disease prescriptions | |||||||
| Rheumatoid arthritis | 60 (48.8) | 39 (40.2) | 21 (80.8) | <0.001 | 18 (36.0) | 42 (57.5) | 0.027 |
| Cardiovascular disease | 51 (41.5) | 35 (36.1) | 16 (61.5) | 0.025 | 20 (40.0) | 31 (42.5) | 0.853 |
| Anticoagulants | 29 (23.6) | 18 (18.6) | 11 (42.3) | 0.018 | 16 (32.0) | 13 (17.8) | 0.085 |
| Central nervous system | 26 (21.1) | 19 (19.6) | 7 (26.9) | 0.425 | 9 (18.0) | 17 (23.3) | 0.510 |
| COPD | 10 (8.1) | 7 (7.2) | 3 (11.5) | 0.439 | 3 (6.0) | 7 (9.6) | 0.739 |
| Oral antidiabetics or insulin | 4 (3.3) | 2 (2.1) | 2 (7.7) | 0.196 | 1 (2.0) | 3 (4.1) | 0.645 |
| Parkinson's disease | 4 (3.3) | 3 (3.1) | 1 (3.8) | 1.000 | 2 (4.0) | 2 (2.7) | 1.000 |
COPD: chronic obstructive pulmonary disease.
Data were compared by two-sample t-test or Fisher's exact test.
aPrescription of glucocorticoids during the six months before the first claim for once-daily teriparatide.
bEarly initiators started treatment during months 1–4 of once-daily teriparatide availability, whereas later initiators started treatment during months 5–8 of once-daily teriparatide availability.
cIncludes alendronate, etidronate, minodronate, and risedronate.
P < 0.05 indicates statistical significance.